A study on stage-four lung adenocarcinoma from the United States [26] reported that TTF-1 immunostaining was a prognostic factor rather than a predictor of the response to platinum-doublet chemotherapy including PEM. The gene discussed is TTF1; the disease is lung adenocarcinoma.